ETF Holdings Breakdown of HUMA

News associated with HUMA

Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of “Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy […] - 2025-06-12 07:56:56

Squarepoint Ops LLC Invests $132,000 in Humacyte, Inc. (NASDAQ:HUMA)

Squarepoint Ops LLC bought a new position in Humacyte, Inc. (NASDAQ:HUMA – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 26,098 shares of the company’s stock, valued at approximately $132,000. Other hedge funds and other institutional investors have also recently modified […] - 2025-06-10 07:26:51

Humacyte, Inc. (NASDAQ:HUMA) Stock Position Raised by ProShare Advisors LLC

ProShare Advisors LLC lifted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 30.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,852 shares of the company’s stock after acquiring an additional 7,188 shares during the […] - 2025-06-02 08:34:50

Humacyte (NASDAQ:HUMA) versus ProKidney (NASDAQ:PROK) Financial Comparison

Humacyte (NASDAQ:HUMA – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Analyst Recommendations This is a summary of current recommendations […] - 2025-05-30 06:08:50

Humacyte, Inc. (NASDAQ:HUMA) Holdings Decreased by Two Sigma Investments LP

Two Sigma Investments LP reduced its stake in shares of Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 919,097 shares of the company’s stock after selling 149,142 shares during the quarter. Two […] - 2025-05-28 08:04:50

Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Consensus Price Target from Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) have earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating […] - 2025-05-21 05:06:53

HC Wainwright Initiates Coverage on Humacyte (NASDAQ:HUMA)

HC Wainwright started coverage on shares of Humacyte (NASDAQ:HUMA – Get Free Report) in a research note issued on Wednesday, MarketBeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 111.64% from the stock’s current price. A number of […] - 2025-05-16 08:46:53

Humacyte, Inc. (NASDAQ:HUMA) Holdings Lowered by Marshall Wace LLP

Marshall Wace LLP decreased its stake in Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 90.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,917 shares of the company’s stock after selling 529,645 shares during the quarter. Marshall Wace LLP’s holdings in Humacyte were worth […] - 2025-05-05 08:37:01

Legal & General Group Plc Acquires 13,293 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Legal & General Group Plc raised its stake in Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 81,405 shares of the company’s stock after buying an additional 13,293 shares during the quarter. Legal […] - 2025-04-30 07:54:52

XTX Topco Ltd Increases Position in Humacyte, Inc. (NASDAQ:HUMA)

XTX Topco Ltd boosted its holdings in Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 29.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,929 shares of the company’s stock after purchasing an additional 9,880 shares during the quarter. XTX Topco Ltd’s holdings in Humacyte […] - 2025-04-28 08:11:10

Charles Schwab Investment Management Inc. Boosts Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Charles Schwab Investment Management Inc. increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 7.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 775,718 shares of the company’s stock after purchasing an additional 54,400 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Humacyte were worth $3,917,000 […] - 2025-03-27 07:13:09

Intech Investment Management LLC Has $304,000 Position in Humacyte, Inc. (NASDAQ:HUMA)

Intech Investment Management LLC grew its position in Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 41.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,178 shares of the company’s stock after acquiring an additional 17,563 shares during the period. […] - 2025-03-26 08:23:10

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. Several other analysts have also recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a […] - 2025-03-10 05:37:45

Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Drops By 6.2%

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 24,040,000 shares, a drop of 6.2% from the January 15th total of 25,640,000 shares. Based on an average daily volume of 4,330,000 shares, the short-interest ratio is […] - 2025-02-19 08:42:38

Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Price Target from Analysts

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-02-14 08:22:52

HUMA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	26,055	USD 72,172 5.1%
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	77,425	USD 171,884
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	77,425	USD 171,884
2025-05-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	362	USD 1,003 5.1%
Total =		181,267	USD 416,943

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer